Intrexon completes acquisition of Medistem

|About: Intrexon Corp (XON)|By:, SA News Editor

Intrexon (XON) finalizes its buy of Medistem, a developer of endometrial regenerative cells (ERC). The company believes that ERCs can potentially be manufactured as genetically modified therapeutics delivery vehicles in the body.

116 mutual funds have positions in the stock.